September 4, 2020 - Abbott (Abbott Park, IL) announced the start of the LIFE-BTK clinical trial to evaluate the safety and effectiveness of the company's new Esprit BTK Everolimus Eluting Resorbable Scaffold System. This is the first Investigational Device Exemption (IDE) trial in the U.S. to evaluate a fully resorbable device to treat blocked arteries below the knees, or … [Read more...]
Abbott’s FreeStyle Libre 2 iCGM system now available to Medicare beneficiaries
September 1, 2020 - Abbott (Abbott Park, IL) announced its next-generation FreeStyle Libre 2 integrated continuous glucose monitoring (iCGM) system is now available to Medicare patients. Having met the codes for therapeutic CGM systems used for coverage by the U.S. Centers for Medicare & Medicaid Services (CMS), the FreeStyle Libre 2 system is now accessible to all … [Read more...]
Quidel provides business update, isn’t concerned by Abbott’s new SARS antigen test
August 28, 2020 - Quidel Corporation (San Diego, CA) yesterday announced business updates and reaffirmed that it is “an industry leader in the introduction of FDA-authorized rapid tests for a wide range of diseases and medical conditions, [and] remains in the forefront of the battle against the COVID-19 pandemic.” Competition Was Expected “Abbott’s entry into the SARS … [Read more...]
Abbott releases fast, $5 COVID-19 antigen test, free mobile app to display test results
August 27, 2020 - Abbott (Abbott Park, IL) has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its BinaxNOW COVID-19 Ag Card rapid test for detection of COVID-19 infection. The company says it will sell this test for $5. Currently, AdvaMed (The Advanced Medical Technology Association) estimates that test manufacturers are … [Read more...]
Abbott releases new research on challenges of caring for cardiovascular patients
August 19, 2020 - New global research released by Abbott (Abbott Park, IL) takes a deep dive into the barriers of cardiovascular patient care and shows that more than 80% of physicians and hospital administrators view technology and data as critical to addressing challenges before, during, and after treatment. The goal of the survey was to uncover how data and technology … [Read more...]
Abbott announces start of study to evaluate new device to treat recurrent AFib
August 04, 2020 - Abbott (Abbott Park, IL) announced first enrollments in the TactiFlex PAF IDE study to evaluate a new device to treat people suffering from paroxysmal atrial fibrillation (PAF), a type of irregular heartbeat. The study will evaluate the performance of the investigational TactiFlex Ablation Catheter, Sensor Enabled (SE) for people whose atrial … [Read more...]
Abbott receives FDA approval for iOS-compatible app for people living with chronic pain
July 23, 2020 - Abbott (Abbott, IL) received approval from the U.S. Food and Drug Administration (FDA) for the use of the company's Patient Controller app on compatible personal Apple smartphone devices. At Abbott, this approval allows patients living with neurological conditions, including chronic pain or movement disorders, the ability to manage therapy directly from their … [Read more...]
Abbott reports Q2 2020 results, exceeds analysts’ expectations
July 17, 2020 – Abbott (Abbott Park, IL) announced financial results for the second quarter ended June 30, 2020. The company reported worldwide sales of $7.3 billion in the second quarter, including $615 million of COVID-19 diagnostic testing-related sales. Abbott also reported that growth rates in business areas initially most impacted by COVID-19 improved significantly over … [Read more...]
Abbott receives FDA approval for new heart rhythm devices featuring Bluetooth connectivity and continuous remote monitoring
Abbott (Abbott Park, IL) announced that the U.S. Food and Drug Administration (FDA) has approved the company's next-generation Gallant implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices. The Bluetooth-enabled devices bring new benefits to patients with heart rhythm disorders, "including a patient-preferred design … [Read more...]
Abbott, Tandem Diabetes Care partner to integrate tech for automated insulin delivery systems
Abbott (Abbott Park, IL) and Tandem Diabetes Care have finalized an agreement to develop and commercialize integrated diabetes solutions that combine Abbott's continuous glucose monitoring (CGM) technology with Tandem's insulin delivery systems to provide more options for people to manage their diabetes. The companies first announced their intention to work together in … [Read more...]